FDA Adds KRAS Testing Info to Vectibix, Erbitux Labels

The FDA has updated the drugs' labels to note that "retrospective analyses of metastatic colorectal cancer trials have not shown a treatment benefit for the EGFR inhibitors in patients whose tumors had KRAS mutations in codon 12 or 13" and that the use of the drugs is not recommended for the treatment of colorectal cancer patients with these mutations.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.